Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rilimogene galvacirepvec-rilimogene glafolivec - BN ImmunoTherapeutics

Drug Profile

Rilimogene galvacirepvec-rilimogene glafolivec - BN ImmunoTherapeutics

Alternative Names: PROSTVAC; PROSTVAC-F; PROSTVAC-V; PROSTVAC-VF-TRICOM; PSA-TRICOM; Rilimogene gamvacirepvec-rilimogene glafolivec; Rilimogene-glafolivec-rilimogene-galvacirepvec; Vaccinia PSA TRICOM-fowlpox PSA TRICOM

Latest Information Update: 23 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer BN ImmunoTherapeutics; National Cancer Institute (USA); University of California at San Francisco
  • Class Antineoplastics; Cancer vaccines; Gene therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 09 Nov 2018 Bristol-Myers Squibb terminates its option and license agreement for rilimogene galvacirepvec-rilimogene glafolivec
  • 09 Nov 2018 Discontinued - Phase-II for Prostate cancer (Adjuvant therapy) in USA (SC)
  • 09 Nov 2018 Discontinued - Phase-III for Prostate cancer (Hormone refractory, Metastatic disease) in USA, Iceland, Spain, Estonia, Puerto Rico, Belgium, United Kingdom, Denmark, Israel, Russia, Canada, Australia, Germany, France, Poland, Netherlands (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top